Company News
Thermo Fisher Scientific produce reliable COVID testing kits
A new state-of-the-art Thermo Fisher Scientific manufacturing facility in Bengaluru are poised to produce COVID-19 testing kits and diagnostic solutions that are made in India for use in India. CoviPath COVID-19 RT-PCR kit, which contains the assays and controls for Thermo Fisher’s gold standard RT-PCR test is intended for the qualitative detection of nucleic acid from SARS-CoV-2 in individuals suspected of COVID-19.
The CoviPath COVID-19 RT-PCR Kit has been approved under MDR 2017 rules for IVD use by the Indian Council for Medical Research (ICMR) and Drug Control General of India (DCGI) in all authorized laboratories. Testing with the kit can be done on Applied Biosystems real-time PCR instruments with FAM dye, VIC dye, and JUN dye or any RT-PCR platform with 3 dye channels in molecular biology laboratories approved for testing. Samples are collected from nasopharyngeal swab, nasopharyngeal aspirate, and bronchoalveolar lavage (BAL) specimens. The CoviPath COVID-19 RT-PCR kit is designed to detect viral targets with low mutations and offers more than 99.5 percent sensitivity and 99.5 percent specificity. The kit is packaged in a user- friendly and convenient pack size of 200 reactions. The company will make these kits available across the country leveraging its strong distribution network.
Amit Chopra
Managing Director, India and South Asia, Thermo Fisher Scientific
“Thermo Fisher has been playing a central role in the fight against COVID-19 pandemic. The introduction of this kit and the new facility strengthens our commitment toward the COVID-19 response in India. The new facility is equipped with the capacity to manufacture up to 10 million tests every month. This facility will be instrumental in ensuring access to affordable testing kits while maintaining global quality standards.”
